Target intelligence / Profile preview

Intestinal mucosal phospholipid layer

Molecular classification
Lipid bilayer, Mucosal barrier component
01

Overview

The intestinal mucosal phospholipid layer is a critical structural component of the gut barrier, primarily located on the luminal surface of the colonic mucus. It consists largely of phosphatidylcholine (PC), which provides a hydrophobic surfactant-like property that protects the underlying intestinal epithelium from chemical and bacterial insults (Ehehalt et al., 2004; PMID: 15188465). In inflammatory conditions such as ulcerative colitis, the concentration of phospholipids in the mucus is significantly reduced, compromising the barrier and allowing for the translocation of bacteria that trigger inflammation (Stremmel et al., 2010; PMID: 20517916). Therapeutic interventions aim to replenish this layer using delayed-release or enteric-coated phosphatidylcholine formulations that bypass the small intestine to reach the colon (Stremmel et al., 2005; PMID: 15825125). Conversely, certain drugs like non-steroidal anti-inflammatory drugs (NSAIDs) can disrupt this layer by associating with the phospholipids, contributing to gastrointestinal toxicity (Lichtenberger et al., 1995; PMID: 7744317). This layer also plays a role in lubricating the intestinal surface, facilitating the passage of stool. Restoring the integrity of this phospholipid barrier is a recognized strategy for maintaining clinical remission in patients with ulcerative colitis. Research continues into how the composition of these lipids changes in response to diet and the gut microbiome.

Other names
Colonic mucus phospholipid layerIntestinal surfactant-like layerMucosal hydrophobic barrier
02

Mechanism of action

Replenishment of the hydrophobic surfactant-like layer on the intestinal mucosa to restore barrier integrity and prevent pro-inflammatory luminal contents from contacting the epithelium.

03

Biological functions

Barrier functionHydrophobic protectionLubricationPrevention of bacterial translocation
04

Disease associations

Ulcerative colitisInflammatory bowel diseaseNSAID-induced enteropathy
05

Safety considerations

Targeted delivery to the colonPotential for altered lipid metabolism
06

Interacting drugs

Phosphatidylcholine

4 more in the full profile.

07

Biomarkers

Mucosal phosphatidylcholine levelsFecal calprotectinEndoscopic mucosal appearance

Beyond the preview

Go deeper on Intestinal mucosal phospholipid layer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal mucosal phospholipid layer.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call